The world of advanced heart failure is relatively small and specialized, but the most important thing learners should know is when to identify a patient who's heading down that slippery slope of advanced heart failure.Read Post
Dr. Bakris has been extensively involved as either a principal investigator or on the steering committees of national and international trials involving diabetic kidney disease progression and resistant hypertension. There are many people with different types of hypertension, isolated, systolic, masked, and white coat hypertension. Continue reading...
Are you prepared for the ECG and Imaging Studies component of the Cardiology Board Exam?
Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions. Mavacamten is an investigational, first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.
Dr. Neil Stone serves as faculty for K2P’s LEGENDS series, where he has provided a talk on the prevention of cardiovascular disease through lipid management.
Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk.
Dr. Hugh Calkins is a member of the K2P Legends Series faculty and has provided a video entitled “Electrophysiology: State of the Science.”
Dr. Deepak Bhatt serves as faculty for K2P’s LEGENDS series, where he has provided a retrospective on coronary artery disease. He also contributes regularly to other K2P activities, providing education and an expert perspective to many of our programs.
Dr. Ty Gluckman is the Curriculum Chair for K2P’s CurrentMD™ Cardiology product, where he helps to strategize and oversee the cardiology curriculum. He also contributes regular content on a variety of topics, including evaluation of chest pain and risk factor assessment.
The American College of Cardiology has released a new Expert Consensus Decision Pathway (ECDP) to address the evaluation and management of some of the more common post-COVID cardiovascular consequences. The effort was co-chaired by Ty Gluckman, MD, MHA, FACC, and Nicole M. Bhave, MD, FACC.
FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.
In our new eBook, we collaborated with physician CME leaders to highlight the gaps in the system and what needs to change to bring CME current and give it optimal efficiency.
Did you opt to postpone sitting for the ABIM CVB exam until October 2021? No matter what factors contributed to your decision, you now have the power to approach your exam preparation as more of a marathon than a sprint.